Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 18 of 18 publications.

Halperin JL, Rothman K. Initial antithrombotic therapy after percutaneous left atrial appendage occlusion: shifting approaches to a moving target. J Am Coll Cardiol. 2023 Oct 31;82(18):1774-6. doi: 10.1016/j.jacc.2023.08.037

Casas G, Limeres J, Oristrell G, Gutierrez-Garcia L, Andreini D, Borregan M, Larrañaga-Moreira JM, Lopez-Sainz A, Codina-Solà M, Teixido-Tura G, Sorolla-Romero JA, Fernández-Álvarez P, González-Carrillo J, Guala A, La Mura L, Soler-Fernández R, Sao Avilés A, Santos-Mateo JJ, Marsal JR, Ribera A, de la Pompa JL, Villacorta E, Jiménez-Jáimez J, Ripoll-Vera T, Bayes-Genis A, Garcia-Pinilla JM, Palomino-Doza J, Tiron C, Pontone G, Bogaert J, Aquaro GD, Gimeno-Blanes JR, Zorio E, Garcia-Pavia P, Barriales-Villa R, Evangelista A, Masci PG, Ferreira-González I, Rodríguez-Palomares JF. Clinical risk prediction in patients with left ventricular myocardial noncompaction. J Am Coll Cardiol. 2021 Aug 17;78(7):643-62. doi: 10.1016/j.jacc.2021.06.016

Dong OM, Friede K, Chanfreau C, Voora D. One-year cost-effectiveness of CYP2C19- guided de-escalation and escalation of P2Y12 inhibitors in veterans with acute coronary syndromes undergoing percutaneous coronary intervention. Presented at the American College of Cardiology’s Virtual 70th Annual Scientific Session and Exposition; May 15, 2021. [abstract] J Am Coll Cardiol. 2021 May; 77(18 Suppl 1):3416.

Ling W, Nadipelli VR, Solem CT, Farabee D, Ronquest NA, Perrochet B, Learned SM, Deshpande CG, Heidbreder C. Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment. Subst Abuse Rehabil. 2019 Jun 5;10:13-21. doi: 10.2147/SAR.S198361

Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018 Sep 21;9:59-78. doi: 10.2147/SAR.S150253

Chamandi C, Barbanti M, Munoz-Garcia A, Latib A, Nombela-Franco L, Gutierrez-Ibanez E, Veiga-Fernandez G, Cheema AN, Cruz-Gonzalez I, Serra V, Tamburino C, Mangieri A, Colombo A, Jimenez-Quevedo P, Elizaga J, Laughlin G, Lee DH, Garcia Del Blanco B, Rodriguez-Gabella T, Marsal JR, Cote M, Philippon F, Rodes-Cabau J. Long-term outcomes in patients with new permanent pacemaker implantation following transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018 Feb 12;11(3):301-10. doi: 10.1016/j.jcin.2017.10.032

Paquette M, Riou Franca L, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS, Rothman KJ, Zint K, Halperin JL, Huisman MV, Lip GYH, Nieuwlaat R. Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation. J Am Coll Cardiol. 2017 Sep 26;70(13):1573-83. doi: 10.1016/j.jacc.2017.07.793

Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY, GLORIA-AF Investigators. The changing landscape for stroke prevention in AF: findings from the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017 Feb 21;69(7):777-85.

Abdul-Jawad Altisent O, Durand E, Munoz-Garcia AJ, Nombela-Franco L, Cheema A, Kefer J, Gutierrez E, Benitez LM, Amat-Santos IJ, Serra V, Eltchaninoff H, Alnasser SM, Elizaga J, Dager A, Garcia Del Blanco B, Ortas-Nadal MDR, Marsal JR, Campelo-Parada F, Regueiro A, Del Trigo M, Dumont E, Puri R, Rodes-Cabau J. Reply: antithrombotic regimen in post-TAVR atrial fibrillation: not an easy decision. JACC Cardiovasc Interv. 2016 Nov 28;9(22):2366-8. doi: 10.1016/j.jcin.2016.09.038

Boscarino JA, Kirchner HL, Pitcavage JM, Nadipelli VR, Ronquest NA, Fitzpatrick MH, Han JJ. Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system. Subst Abuse Rehabil. 2016 Sep 16;7:131-41. doi: 10.2147/SAR.S108302

Abdul-Jawad Altisent O, Durand E, Munoz-Garcia AJ, Nombela-Franco L, Cheema A, Kefer J, Gutierrez E, Benitez LM, Amat-Santos IJ, Serra V, Eltchaninoff H, Alnasser SM, Elizaga J, Dager A, Garcia Del Blanco B, Ortas-Nadal Mdel R, Marsal JR, Campelo-Parada F, Regueiro A, Del Trigo M, Dumont E, Puri R, Rodes-Cabau J. Warfarin and antiplatelet therapy versus Warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2016 Aug 22;9(16):1706-17. doi: 10.1016/j.jcin.2016.06.025

Garcia-Albeniz X, Hsu J, Lipsitch M, Bretthauer M, Logan RW, Hernandez-Diaz S, Hernan MA. Colonoscopy and risk of infective endocarditis in the elderly. J Am Coll Cardiol. 2016 Aug 2;68(5):570-1. doi: 10.1016/j.jacc.2016.05.041

Ferreira-Gonzalez I, Marsal JR, Ribera A, Permanyer-Miralda G, Garcia-Del Blanco B, Marti G, Cascant P, Masotti-Centol M, Carrillo X, Mauri J, Batalla N, Larrousse E, Martin E, Serra A, Rumoroso JR, Ruiz-Salmeron R, De La Torre JM, Cequier A, Gomez-Hospital JA, Alfonso F, Martin-Yuste V, Sabate M, Garcia-Dorado D. Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. J Am Coll Cardiol. 2012 Oct 9;60(15):1333-9. doi: 10.1016/j.jacc.2012.04.057

Jacquemin B, Antoniades C, Nyberg F, Plana E, Muller M, Greven S. Common genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. J Am Coll Cardiol. 2008 Sep 9;52(11):941-52.

Anthony MS, Clarkson TB. Does extent of pretreatment atherosclerosis influence the effects of conjugated equine estrogens on atherosclerosis progression? Presented at the 51st Annual Scientific Session of the American College of Cardiology; March 17, 2002. Atlanta, GA. [abstract] J Am Coll Cardiol. 2002 Mar; 39:248A.

Ward A, Caro JJ, Green T, Huybrechts K, Arana A, Wait S, Eleftheriou A. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol. 2002;2(3).

Palka P, Lange A, Fleming AD, Donnelly JE, Dutka DP, Starkey IR, Shaw TR, Sutherland GR, Fox KA. Differences in myocardial velocity gradient measured throughout the cardiac cycle in patients with hypertrophic cardiomyopathy, athletes and patients with left ventricular hypertrophy due to hypertension. J Am Coll Cardiol. 1997 Sep 1;30(3):760-8. doi: 10.1016/s0735-1097(97)00231-3

Palka P, Lange A, Fleming AD, Fenn LN, Shaw TRD, Starkey IR, Fox KAA, McDicken WN, Sutherland GR. Assessment of transmural velocity gradients in hypertrophic hearts-A new diagnostic index for hypetrophic cardiomyopathy. J Am Coll Cardiol. 1996 Feb 1;27(2_supplement_1):21.